Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Serina Therapeutics, Inc.SER · Entity 9581 | Chief Scientific Officer | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Serina Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2036-05-21 | Direct | 85,558 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 85,558 · Balance 85,558 F1: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 23:33 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 85,558 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001301120-26-000021 · wk-form4_1779838407.xml · derivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,558 Underlying: Common Stock · 85,558 shares Expires 2036-05-21 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 23:24 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000018 · wk-form4_1774394662.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,686 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 23:24 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 6,500 | $2.86 | $18,567.90 |
DisclosureSEC source: 0001301120-26-000018 · wk-form4_1774394662.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: 1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $3.03. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 23:24 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-26-000018 · wk-form4_1774394662.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 18:20 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 39,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000016 · wk-form4_1774030842.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,186 Underlying: Common Stock · 39,000 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 18:20 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 39,000 | $2.50 | $97,500.00 |
DisclosureSEC source: 0001301120-26-000016 · wk-form4_1774030842.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 18:20 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 39,000 | $0.06 | $2,340.00 |
DisclosureSEC source: 0001301120-26-000016 · wk-form4_1774030842.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2026 Filed Feb 17, 2026 13:35 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001301120-26-000014 · wk-form4_1771335355.xml · derivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 17:35 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000012 · wk-form4_1770140133.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,186 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 17:35 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 6,500 | $3.03 | $19,680.05 |
DisclosureSEC source: 0001301120-26-000012 · wk-form4_1770140133.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.00. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 17:35 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-26-000012 · wk-form4_1770140133.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 17:54 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000010 · wk-form4_1769709237.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 319,686 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 17:54 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 6,500 | $3.57 | $23,185.50 |
DisclosureSEC source: 0001301120-26-000010 · wk-form4_1769709237.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.59 to $3.55. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 17:54 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-26-000010 · wk-form4_1769709237.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 17:35 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000008 · wk-form4_1769189706.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 326,186 Underlying: Common Stock · 2,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 17:35 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 2,500 | $2.95 | $7,375.00 |
DisclosureSEC source: 0001301120-26-000008 · wk-form4_1769189706.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 17:35 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 2,500 | $0.06 | $150.00 |
DisclosureSEC source: 0001301120-26-000008 · wk-form4_1769189706.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 00:17 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 328,686 Underlying: Common Stock · 2,000 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 00:17 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 2,000 | $3.00 | $6,000.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 00:17 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 2,000 | $0.06 | $120.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 00:17 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,686 Underlying: Common Stock · 2,000 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 00:17 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 2,000 | $3.07 | $6,140.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 00:17 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 2,000 | $0.06 | $120.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2026 Filed Jan 14, 2026 17:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 1,084 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 332,686 Underlying: Common Stock · 1,084 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 14, 2026 Filed Jan 14, 2026 17:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 1,084 | $2.50 | $2,713.36 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.50. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 14, 2026 Filed Jan 14, 2026 17:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 1,084 | $0.06 | $65.04 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 17:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 5,416 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,770 Underlying: Common Stock · 5,416 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 17:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 5,416 | $2.50 | $13,540.00 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 13, 2026 Filed Jan 14, 2026 17:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 5,416 | $0.06 | $324.96 |
DisclosureSEC source: 0001301120-26-000004 · wk-form4_1768413405.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 17:27 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000002 · wk-form4_1767979647.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,186 Underlying: Common Stock · 13,000 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 17:27 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 13,000 | $2.69 | $34,953.10 |
DisclosureSEC source: 0001301120-26-000002 · wk-form4_1767979647.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.60. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F1 · balance_after: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.60. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 17:27 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 13,000 | $0.06 | $780.00 |
DisclosureSEC source: 0001301120-26-000002 · wk-form4_1767979647.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:40 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 4,100 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000039 · wk-form4_1767026407.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,186 Underlying: Common Stock · 4,100 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:40 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 4,100 | $2.60 | $10,660.00 |
DisclosureSEC source: 0001301120-25-000039 · wk-form4_1767026407.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:40 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 4,100 | $0.06 | $246.00 |
DisclosureSEC source: 0001301120-25-000039 · wk-form4_1767026407.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 19:04 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 5,673 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000037 · wk-form4_1766516671.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 356,286 Underlying: Common Stock · 5,673 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 19:04 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 5,673 | $2.67 | $15,167.90 |
DisclosureSEC source: 0001301120-25-000037 · wk-form4_1766516671.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.705 to $2.66. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 19:04 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 5,673 | $0.06 | $340.38 |
DisclosureSEC source: 0001301120-25-000037 · wk-form4_1766516671.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 3,227 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000035 · wk-form4_1766019414.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 361,959 Underlying: Common Stock · 3,227 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 3,227 | $2.96 | $9,561.92 |
DisclosureSEC source: 0001301120-25-000035 · wk-form4_1766019414.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $2.96. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 3,227 | $0.06 | $193.62 |
DisclosureSEC source: 0001301120-25-000035 · wk-form4_1766019414.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:59 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000033 · wk-form4_1765929561.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 365,186 Underlying: Common Stock · 1,700 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:59 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 1,700 | $3.26 | $5,541.49 |
DisclosureSEC source: 0001301120-25-000033 · wk-form4_1765929561.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.275. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:59 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 1,700 | $0.06 | $102.00 |
DisclosureSEC source: 0001301120-25-000033 · wk-form4_1765929561.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 17:48 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 3,555 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000030 · wk-form4_1765561686.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 366,886 Underlying: Common Stock · 3,555 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 17:48 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 3,555 | $3.24 | $11,519.62 |
DisclosureSEC source: 0001301120-25-000030 · wk-form4_1765561686.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.35. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 17:48 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 3,555 | $0.06 | $213.30 |
DisclosureSEC source: 0001301120-25-000030 · wk-form4_1765561686.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 21:11 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 645 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 370,441 Underlying: Common Stock · 645 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 21:11 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 645 | $3.35 | $2,160.75 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 21:11 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantCommon Stock | 645 | $0.06 | $38.70 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 645 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.